



The 65th ASH Annual Meeting Abstracts

ORAL ABSTRACTS

732.ALLOGENEIC TRANSPLANTATION: DISEASE RESPONSE AND COMPARATIVE TREATMENT STUDIES

A Multicenter Analysis of Allogeneic Transplant Outcomes in Patients with Philadelphia-like (Ph-like) Acute Lymphoblastic Leukemia (ALL)

Zaid Abdel Rahman, MD¹, Paul B. Koller, MD², Tamer Othman, MD³, Rima M. Saliba, PhD⁴, Yenny Alejandra Moreno Vanegas, MD⁵, Razan Mohty, MD⁶, Celina Ledesma⁴, Gabriela Rondon, MD⁷, Nitin Jain, MD⁸, Elias Jabbour, MD⁹, Vinod Pullarkat, MD¹⁰, Hassan Alkhateeb, MD¹¹, Hagop M. Kantarjian, MD⁸, Patricia Greipp, DO¹², Ryotaro Nakamura, MD¹³, Mohamed A. Kharfan-Dabaja, MD MBA¹⁴, Richard E. Champlin, MD⁴, Stephen J. Forman, MD FACP¹⁵, Elizabeth J. Shpall, MD⁴, Mark R. Litzow, MD¹¹, James M. Foran, MD¹⁶, Ibrahim Aldoss, MD¹⁷, Partow Kebriaei, MD⁴

¹King Hussein Cancer Center, Amman, Jordan

²Hematology/HCT, City of Hope National Medical Center, Duarte, CA

³City of Hope, San Lorenzo, CA

⁴Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

⁵Mayo Clinic, Jacksonville, FL

⁶H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

⁷University of Texas MD Anderson Cancer Center, Houston, TX

⁸Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

⁹University of Texas M.D. Anderson Cancer Ctr., Houston, TX

¹⁰Department of Hematology and Hematopoietic Cell Transplantation and Gehr Family Center for Leukemia Research, City of Hope Comprehensive Cancer Center, Duarte, CA

¹¹Division of Hematology, Mayo Clinic, Rochester, MN

¹²Division of Hematopathology, Mayo Clinic, Rochester, MN

¹³Cellular Immunotherapy Center, Department of Hematology and Hematopoietic Cell Transplantation, Beckman Research Institute of City of Hope, Duarte, CA

¹⁴Department of Hematology/Oncology, Mayo Clinic, Jacksonville, FL

¹⁵Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope National Medical Center, Duarte, CA

¹⁶Hematology/Oncology, Mayo Clinic, Jacksonville, FL

¹⁷City of Hope, Duarte, CA

Background: Ph-like ALL is a high-risk subset of B-lineage ALL that responds poorly to standard chemotherapy regimens. While allogeneic hematopoietic cell transplantation (HCT) is routinely recommended for patients with Ph-like ALL, large multicenter data addressing its role is limited. Here, we conducted a multicenter study to evaluate the role of HCT in adolescent and young adult (AYA) and adult patients (pts) with Ph-like ALL and compare their outcomes to pts with Ph-pos and Ph-neg (non-Ph-like) ALL.

Methods: The study included pts (age ≥ 18) with B-lineage ALL who received HCT in first complete remission (CR1) at 3 academic centers (MD Anderson Cancer Center, City of Hope and Mayo Clinic) between 2006 and 2021. Pts were divided into 3 main subgroups: Ph-like, Ph-pos and Ph-neg ALL. Ph-like ALL cases were identified using cumulative data obtained by targeted RNA sequencing, conventional cytogenetics, FISH studies, whole genome chromosomal microarray and flow cytometry. Measurable residual disease (MRD) prior to HCT was measured using flow cytometry with a sensitivity of 0.01% for Ph-neg and Ph-like ALL, and with a PCR assay for *BCR::ABL1* for Ph-pos ALL. MRD-negativity was defined as $<0.01\%$. Predictors of relapse were evaluated in univariate and multivariate analysis using Fine-Gray sub-distribution hazard models considering non-relapse mortality (NRM) as a competing risk.

Results: 673 patients were identified, 83 (12.3%) had Ph-like ALL, of which 73% had *CRLF2*-alterations. The remaining patients were classified either as Ph-pos (N=271, 40.3%) or Ph-neg ALL (N=319, 47.4%). Patients with Ph-like ALL were younger (median

age 40 years vs 48 and 46 years for Ph-pos and Ph-neg ALL, respectively, $p=0.01$), more likely to be of Hispanic ethnicity (69% vs 32% and 48% for Ph-pos and Ph-neg ALL respectively, $p<0.001$). Patients with Ph-like ALL were also more likely to have induction failure (24% vs 2% and 11% for Ph-pos and Ph-neg ALL, respectively, $p=0.001$). A summary of pts characteristics for each subgroup can be found in Table 1.

The median follow-up was 30, 52 and 48 months for patients with Ph-like, Ph-pos and Ph-neg ALL, respectively. In univariate analysis, 3-yr OS and PFS did not differ significantly (66% and 59% vs 59% and 54%, $p=0.1$) between patients with Ph-like and Ph-neg ALL, respectively. Similarly, the cumulative incidence of relapse was comparable between patients with Ph-like and Ph-neg ALL (22% vs 20%, respectively, $p=0.7$).

In contrast, the 3-yr OS (75%, $p<0.001$) and PFS (70%, $p=0.001$) were significantly higher and relapse rate significantly lower (12%, $p=0.003$) in pts with Ph-pos ALL compared with Ph-like or Ph-neg ALL (Figure 1). The inferior survival in patients with Ph-like and Ph-neg ALL was likely attributable to higher relapse rates (22% and 20% vs 12%, respectively, $p=0.003$) compared to Ph-pos ALL. Finally, the 3-yr NRM rate in patients with Ph-like ALL was comparable (20% vs 18% and 23%, respectively, $p>0.1$) to Ph-pos and Ph-neg ALL.

We confirmed that the relapse rate in patients with Ph-like ALL was comparable to the rate in pts with Ph-neg ALL (HR=1.02, 95% CI 0.6-1.8, $p=0.9$) on multivariate analysis (MVA). Ph-pos ALL was associated with a significantly lower relapse rate compared with Ph-neg ALL (HR=0.4, 95% CI 0.3-0.7, $p<0.001$). MRD positivity prior to allo-HCT was the only additional significant predictor for relapse on MVA (HR=2.9, 95% CI 1.8-4.7, $p<0.001$).

Conclusions: HCT appears to overcome the poor prognosis of patients with Ph-like ALL. Despite higher induction failure rates, patients with Ph-like ALL undergoing HCT in CR1 had similar outcomes to other Ph-neg ALL subsets. The impact of effective salvage therapy leading to MRD-negativity in CR1 in this group is under investigation and will be reported. Further studies are needed to assess the impact of different Ph-like alterations on HCT outcomes. Outcomes for patients with Ph-pos ALL are significantly better than other groups, likely due to the use of TKIs pre- and post-HCT.

Disclosures Koller: *treadwell therapeutics:* Consultancy, Other: safety review committee; *takeda:* Consultancy, Speakers Bureau; *NOVARTIS:* Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. **Jain:** *Medisix:* Research Funding; *BMS:* Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; *Aprea Therapeutics:* Research Funding; *AbbVie:* Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; *AstraZeneca:* Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; *Ipsen:* Consultancy, Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES; *Genentech:* Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; *TG Therapeutics:* Consultancy, Honoraria, Other: Travel, Accommodations, Expenses; *Novalgen:* Research Funding; *Newave:* Research Funding; *MEI Pharma:* Consultancy, Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES; *Fate Therapeutics:* Research Funding; *Takeda:* Research Funding; *TransThera Sciences:* Research Funding; *CareDX:* Consultancy, Honoraria, Other: Travel, Accommodations, Expenses; *Pfizer:* Research Funding; *Dialectic Therapeutics:* Research Funding; *Loxo Oncology:* Research Funding; *Mingsight:* Research Funding; *Janssen:* Consultancy, Honoraria, Other: Travel, Accommodations, Expenses; *Servier:* Research Funding; *Pharmacyclics:* Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; *Incyte:* Research Funding; *ADC Therapeutics:* Research Funding; *Kite/Gilead:* Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; *Cellectis:* Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; *Adaptive Biotechnologies:* Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; *Beigene:* Consultancy, Honoraria, Other: Travel, Accommodations, Expenses; *Precision Biosciences:* Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding. **Jabbour:** *AbbVie:* Consultancy, Honoraria, Research Funding; *Adaptive Biotech:* Consultancy, Honoraria, Research Funding; *Genentech:* Consultancy, Honoraria, Research Funding; *Ascentage Pharma Group:* Consultancy, Honoraria, Research Funding; *Bristol-Myers Squibb:* Consultancy, Honoraria, Research Funding; *Pfizer:* Consultancy, Honoraria, Research Funding; *Takeda:* Consultancy, Honoraria, Research Funding; *Amgen:* Consultancy, Honoraria, Research Funding; *Hikma Pharmaceuticals:* Consultancy, Honoraria, Research Funding. **Pullarkat:** *Pfizer:* Consultancy, Speakers Bureau; *Jazz Pharmaceuticals:* Consultancy, Speakers Bureau; *Servier:* Consultancy, Speakers Bureau; *Novartis:* Consultancy, Speakers Bureau; *Amgen:* Consultancy, Speakers Bureau; *Genentech:* Consultancy, Speakers Bureau; *AbbVie:* Consultancy, Speakers Bureau. **Alkhateeb:** *Mayo Clinic:* Current Employment. **Kantarjian:** *AbbVie:* Consultancy, Honoraria; *Novartis:* Honoraria; *Pfizer:* Honoraria; *KAHR Medical:* Honoraria; *Jazz Pharmaceuticals (Inst):* Honoraria, Research Funding; *Ipsen:* Honoraria; *Immunogen (Inst):* Honoraria, Research Funding; *Daiichi-Sankyo (Inst):* Honoraria, Research Funding; *AstraZeneca/MedImmune:* Honoraria; *Astellas Pharma:* Honoraria; *Ascentage Pharma Group:* Honoraria; *Amgen:* Honoraria; *Precision Biosciences:* Honoraria; *Shenzhen Target Rx:* Honoraria; *Taiho Pharmaceutical:* Honoraria; *AbbVie (Inst):* Research Funding; *Amgen (Inst):* Research Funding; *Ascentage Pharma (Inst):* Research Funding; *Bristol-Myers Squibb (Inst):* Research Funding; *Novartis (Inst):* Research Funding. **Nakamura:** *Leukemia & Lymphoma Society:* Other: grant reviewer; *BMT CTN Steering Committee:* Membership on an entity's Board of Directors or advisory committees; *NCTN Lymphoma Steering Committee:* Membership on an entity's Board of Directors or advisory committees; *Mt. Sinai:* Other: Acute GVHD; *International Consortium:* Other: consortium chair; *Omeros:* Consultancy; *Jazz Pharmaceuticals:* Consultancy, Other: research collaboration; *Sanofi:* Consultancy; *Napajen:* Consultancy; *Blue Bird:* Consultancy; *Miyarisan:* Research Funding; *NCCN:* Other: guideline panel for HCT. **Champlin:** *Takeda Corporation:* Patents & Royalties; *Cell Source:* Research Funding; *Orca Bio:* Consultancy; *Arog:* Consultancy; *Kadmon:* Consultancy; *Actinium Pharmaceuticals:* Consultancy; *Omeros:* Consultancy; *Johnson & Johnson/Janssen:* Consultancy. **Shpall:** *Affimed:* Other: License agreement; *Fibrobiologics:* Membership on an entity's Board of Directors or advisory committees;

Takeda: Other: License agreement; Axio: Membership on an entity's Board of Directors or advisory committees; Adaptimmune: Membership on an entity's Board of Directors or advisory committees; Navan: Membership on an entity's Board of Directors or advisory committees; Celaid Therapeutics: Membership on an entity's Board of Directors or advisory committees; NY Blood Center: Membership on an entity's Board of Directors or advisory committees; Syena: Other: License agreement. **Foran:** CTI: Membership on an entity's Board of Directors or advisory committees; Astellas: Research Funding; BeiGene: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; Actinium: Research Funding; Kura: Research Funding; Sellas: Research Funding; Roivant: Research Funding; Novartis: Research Funding; Celgene: Research Funding; NCI: Membership on an entity's Board of Directors or advisory committees. **Aldoss:** Amgen: Consultancy, Honoraria; Sobi: Consultancy; Pfizer: Consultancy; Jazz: Consultancy; Takeda: Consultancy; KiTE: Consultancy. **Kebrlaci:** Pfizer: Consultancy, Honoraria; Jazz: Consultancy, Honoraria.

Table 1. Patient characteristics and treatment outcomes

Characteristics	Ph-like (N=83)	Ph-pos (N=271)	Ph-neg (N=319)
Age at allo-HCT, years			
Median (range) [IQR]	40 (18-71) [28, 52]	48 (18-72) [36, 58]	46 (18-77)
≤35	28 (34)	61 (22)	97 (30)
36-45	22 (26)	54 (20)	57 (18)
46-55	14 (17)	73 (27)	64 (20)
>55	19 (23)	83 (31)	101 (32)
Race (%)			
White	63 (76)	224 (83)	245 (77)
Black	0 (0)	9 (0.03)	7 (0.02)
Hispanic ethnicity (%)	57 (69)	87 (32)	152 (48)
Sex			
F	28 (34)	126 (46)	155 (49)
M	55 (66)	145 (53)	164 (51)
HCT-CI			
≤3	2 (0-9) [1,4]	2 (0-9) [0,3]	2 (0-10)
≥3	34 (44)	89 (34)	120 (40)
Donor			
MRD	30 (36)	85 (31)	132 (41)
MUD	34 (41)	117 (43)	114 (36)
Haplo	13 (16)	31 (11)	48 (15)
Other	6 (7)	38 (14)	25 (8)
Cell source			
PB	65 (78)	240 (89)	257 (81)
BM	16 (19)	16 (6)	48 (15)
CBT	2 (2)	15 (5)	14 (4)
MRD prior to HCT			
Positive	7 (8)	48 (18)	40 (12)
Negative	69 (83)	126 (46)	215 (67)
Missing	7 (8)	97 (36)	64 (20)
Conditioning			
MAC	63 (76)	193 (71)	227 (71)
RIC/NMA	20 (24)	78 (29)	92 (29)
Induction chemo			
HCVD	44 (53)	173 (64)	209 (66)
Pediatric regimens	30 (36)	41 (15)	73 (23)
ECOG	2 (2)	9 (3)	13 (4)
Other	7 (8)	47 (17)	23 (7)
Response to induction			
Yes	63 (76)	260 (98)	281 (89)
No	20 (24)	6 (2)	34 (11)

Table 1 (cont): Univariate Outcomes			
Median OS (months)	34	Not reached	87
Median PFS (months)	43	Not reached	62
%OS - 3 years	66% (53-75)	75% (69-80)	59% (53-64)
%PFS - 3 years	59% (47-70)	70% (64-75)	54% (48-60)
%Relapse - 3 years	20% (13-32)	12% (9-17)	22% (18-27)
%NRM - 1 year	14% (8-25)	13% (9-17)	16% (13-21)
%NRM - 3 years	20% (13-32)	18% (14-24)	23% (18-28)

Figure 1: Overall Survival




Figure 1

<https://doi.org/10.1182/blood-2023-178150>

Downloaded from http://ashpublications.net/blood/article-pdf/142/Supplement_1/656/2184114/blood-2023-178150.pdf by guest on 18 May 2024